| 引用本文: | 刘茂柏,李娜,郑斌,蔡鸿福,庄茜.普罗布考抗动脉粥样硬化作用的meta分析[J].中国现代应用药学,2017,34(4):579-586. |
| LIU Maobai,LI Na,ZHENG Bin,CAI Hongfu,ZHUANG Qian.Clinical Efficacy on Probucol against Atherosclerosi: A Meta-analysis[J].Chin J Mod Appl Pharm(中国现代应用药学),2017,34(4):579-586. |
|
| 摘要: |
| 目的 通过系统评价有关普罗布考抗动脉粥样硬化作用的文献，评估普罗布考对动脉粥样硬化及预防再狭窄的有效性。方法 在Medline数据库、Embase数据库和Cochrane图书馆和中国期刊全文数据库（CNKI）、VIP、万方数据库、中国生物医学文献数据库（CBM）中检索有关普罗布考抗动脉粥样硬化的随机对照试验，并且对纳入研究进行方法学质量评价，提取文献中有效数据采用RevMan 5.3软件进行 meta分析。结果 共纳入20项随机对照试验，合计1 314例患者。Meta分析结果显示，预防PTCA 再狭窄支架管腔面积[WMD 0.80，95%CI（0.41~1.20），P<0.000 01]、管腔直径[WMD 0.24，95%CI（0.17~0.30），P<0.000 01]、再狭窄率[RR=0.66，95%CI（0.56~0.78），P<0.000 01]、再狭窄程度[WMD=-11.20，95%CI（-17.02~5.38），P=0.000 02]、临床不良事件发生率[RR=0.57，95%CI（0.48~0.67），P<0.000 01]方面均优于对照组，差异有统计学意义。结论 普罗布考能够改善患者动脉粥样硬化状况，有效预防支架术后再狭窄。 |
| 关键词: 普罗布考 动脉粥样硬化 再狭窄 meta分析 |
| DOI：10.13748/j.cnki.issn1007-7693.2017.04.023 |
| 分类号: |
| 基金项目:福建省卫计委中青年骨干人才培养项目（2014-ZQN-JC-15）；福建省社会科学规划项目（2014C042） |
|
| Clinical Efficacy on Probucol against Atherosclerosi: A Meta-analysis |
|
LIU Maobai, LI Na, ZHENG Bin, CAI Hongfu, ZHUANG Qian
|
|
Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou 350001, China
|
| Abstract: |
| OBJECTIVE To evaluate efficacy of probucol against atherosclerosi by systematic review. METHODS Relevant RCTs were identified by searching electronic databases including Medline, Embase, Cochrane Library, VIP, CNKI, Wanfang data, CBM. It was collected by randomized controll trials (RCT) to compare probucol with placebo and no treatment or other convention. The methodological quality of extracted data were assessed, meta-analysis was performed using RevMan 5.3 software. RESULTS A total of 20 studies, involving 1 314 patients were included. Results of meta-analysis showed that lumenarea [WMD 0.80, 95%CI(0.41-1.20), P<0.000 01], inimal lumen diameter [WMD 0.24, 95%CI(0.17-0.30), P<0.000 01], incidence of restenosis [RR=0.66, 95% CI(0.56-0.78), P<0.000 01], degree of restenosis [WMD=-11. 20, 95% CI(-17. 02-5.38), P=0.000 02], adverse events of atherosclerosis [RR=0.57, 95% CI(0.48-0.67), P<0.000 01] of probucol group were better than those of control group, there was statistical significance. CONCLUSION Probucol can decrease the incidence of restenosis and atherosclerosis related events and preserve minimal lumen diameter and lumen area significantly. |
| Key words: probucol atherosclerosis restenosis meta analysis |
